• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>MCI

MCI

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Cytox and Affymetrix Form Strategic Partnership to Develop and Commercialize Blood-Based Genetic Assay for Alzheimer’s Disease Risk Assessment

    Cytox and Affymetrix Form Strategic Partnership to Develop and Commercialize Blood-Based Genetic Assay for Alzheimer’s Disease Risk Assessment

  2. Business Cycle Update: Europe Turning the Cyclical Corner

    PAETEC PAET, one of the largest remaining competitive local exchange carriers in the United States, has announced plans to acquire privately held McLeodUSA. The deal makes strategic sense, in our view, but the financial upside is limited. Therefore, we are leaving our fair value estimate for PAETEC ...

  3. When the Bond Market Was Broken

    Morningstar's Dave Sekera describes the market breakdown after Lehman, the state of the bond market now, and investors' heightened attention to systemic risk today.

  4. Bernanke’s Temporary Reprieve

    Qwest Communications International Q continued to cut costs during the third quarter while holding revenue roughly flat, putting it on pace to roughly meet our expectations for the year. The firm did see a sharp acceleration in the number of phone customers lost during the quarter, but we don't ...

  5. The End of Ethics--and a Way Back

    A new book argues that a return to virtue--honesty and trust--is critically important for capital markets to fully function.

  6. Midyear Review for Fixed-Income CEFs

    We take a look at 2012's CEF performance, distributions changes, and IPOs.

  7. The New Case for High Yield

    Tim Gramatovich is the CIO of Peritus Asset Management, and the Portfolio Manager of the AdvisorShares Peritus High Yield ETF (NYSE: HYLD)

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.